Physician profile
Sara Narayan
NPI 1992998405
$3,432.36
in general payments reported to CMS, 2019-2025
15 companies · $578 in 2025
The $578 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $37.59 · 2021: $39.58 · 2022: $317 · 2023: $1,090 · 2024: $1,011 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,655 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,654.62 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,625.01 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Amgen INC. | $648.77 | 2021-2024 | Tezspire |
| Glaxosmithkline, LLC. | $260.89 | 2019-2025 | Nucala, Trelegy Ellipta |
| Kaleo, INC. | $175.23 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $163.63 | 2023-2024 | Xolair |
| Pfizer INC. | $151.04 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.74 | 2022-2024 | Cuvitru |
| Regeneron Healthcare Solutions, INC. | $93.95 | 2022-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $41.87 | 2020-2022 | |
| Incyte Corporation | $38.52 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Pharming Healthcare, INC. | $24.50 | 2023 | Ruconest |
| Csl Behring | $21.19 | 2024 | Haegarda |
| Grifols USA, LLC | $21.03 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $14.99 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.